ArticleChina CDC weekly2025
Viral Load Dynamics of Chikungunya Virus in Human Specimens - Foshan City, Guangdong Province, China, 2025.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- An ECSA-lineage chikungunya outbreak in Foshan, China: age-stratified clinical and virological profiles.Emerging microbes & infections · 2026Article
- Capsid inclusion in a CHIKV mRNA vaccine impairs adaptive immune responses.Cell reports. Medicine · 2026Article
- Chikungunya virus: global epidemiology, transmission dynamics, and emerging challenges for public health.Infection · 2026Review
- Tupaia belangeri better reflects the typical symptoms of Chikungunya virus infection than mice: A comparative study.Virologica Sinica · 2026Article
- Dual-Model framework for CHIKV transmission modeling: ODE and Petri Net Analysis of the 2025 Foshan outbreak.BMC public health · 2026Article
- Research advances in chikungunya virus: Epidemiology, pathogenesis, and control.One health (Amsterdam, Netherlands) · 2026Review
- A Local Chikungunya Fever Outbreak Field Investigation - Fujian Province, China, 2025.China CDC weekly · 2026Article
- Comparative Analysis of Next- and Third-Generation Sequencing Platforms for Chikungunya Virus Whole-Genome Sequencing Using a Lineage-Inclusive Primer Set During the 2025 Foshan Outbreak.Tropical medicine and infectious disease · 2026Article
- Clinical epidemiology and viral genomics insights from a Chikungunya fever outbreak in South China, 2025.Frontiers in cellular and infection microbiology · 2026Article
- Epidemiology, transmission, vector and factors analysis of chikungunya outbreak in 2025, Quanzhou City of China.Frontiers in public health · 2026Article
- The First Imported Case of Chikungunya Virus Infection - Anhui Province, China, 2025.China CDC weekly · 2025Article
- Isolation and genomic characterization of Chikungunya virus during the 2025 outbreak in Foshan, China.Emerging microbes & infections · 2025Article
- Re-emergence of chikungunya virus in China by 2025: What we know and what to do?PLoS pathogens · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Chikungunya virus (CHIKV) represents an Aedes-borne alphavirus that causes fever, rash, and severe arthralgia. Outbreaks have expanded across 119 countries, with sporadic imported cases documented in China. While serum has been regarded as the optimal diagnostic specimen, comprehensive data comparing multiple specimen types across all infection phases have remained lacking. What is added by this report?: Using 1,156 samples from the 2025 Foshan outbreak, we quantified CHIKV RNA levels from 6 days before to 12 days after symptom onset. Serum consistently yielded the highest viral loads, while saliva, urine, and throat swabs demonstrated inferior performance. Viral RNA detection was achievable as early as 1 day before symptom onset. Days 0-7 post-symptom onset constitute the phase of explosive viral replication, representing the optimal timeframe for specimen collection to minimize false-negative results. From Day 8 onward, antibody IgG testing should be incorporated to prevent diagnostic gaps. What are the implications for public health practice?: Pre-symptomatic polymerase chain reaction (PCR) testing of serum (day-1) enables interception of imported cases at ports of entry; days 0-7 represent the optimal clinical sampling window to minimize false negatives. After day 8, antibody testing must supplement molecular diagnostics. This systematic analysis of CHIKV viral-load kinetics provides critical evidence for calibrating quarantine duration, optimizing contact-tracing intensity, and allocating resources effectively, thereby reducing community transmission risk substantially.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.